Category: Local News

Categories
Local News Politics

NJ Gov. Phil Murphy re-elected after defeating challenger in tight gubernatorial race

TRENTON, N.J. (AP) — New Jersey Democratic Gov. Phil Murphy narrowly won reelection Wednesday, eking out a victory that spared Democrats the loss of a second gubernatorial seat.

 

He’s the state’s first Democratic governor to get a second straight term in 44 years, defeating Republican former Assembly member Jack Ciattarelli.

 

AP called the race Wednesday evening when a new batch of votes from Republican-leaning Monmouth County increased Murphy’s lead and closed the door to a Ciattarelli comeback.

 

Ballots remaining to be counted included a significant number of votes from predominantly Democratic Essex County, along with mail-in votes spread across other counties. Murphy has won the mail-in vote by a wide margin even in Republican leaning counties like Monmouth.

 

Ciattarelli spokesperson Stami Williams disputed the call because of the close margin, calling it “irresponsible.”

 

Murphy delivered a brief speech in Asbury Park’s boardwalk convention hall, nodding to the race’s narrow margin by saying he would work for both those who voted for and against him. But there was no trace he planned to scale back the left-leaning positions he’s taken during his first term.

 

“We shall be judged in the long run not by how we fared in elections, but by what we did as an administration,” Murphy said, quoting Brendan Byrne, the last Democratic governor to be reelected in the state. “Those words will always remind us to always, always, always keep moving forward.”

 

Ciattarelli waged a formidable campaign in heavily Democratic New Jersey, his spending nearly equaling the governor’s and outpacing the GOP’s performance four years ago. But Murphy’s advantages, including 1 million more registered Democrats, proved too much for the Republican to overcome.

 

The victory gives Democrats a silver lining after GOP businessman Glenn Youngkin defeated Terry McAuliffe in Virginia’s gubernatorial race — exacerbating worries that President Joe Biden’s sagging approval ratings are hurting the party. This year’s elections were the first major tests of voter sentiment since Biden took office and pointed to a potentially painful year ahead for Democrats as they try to maintain thin majorities in Congress.

 

The closeness of the race has surprised experts, who watched public polls showing Murphy leading comfortably and looked to his party’s registration advantage.

 

“If you asked anybody several months ago within the state, I think anyone would have predicted a high double digit landslide for Murphy,” said Ashley Koning, director of the Eagleton Center for Public Interest Polling at Rutgers University.

 

Voters came out at much higher rates for Ciattarelli this year than they did for his GOP predecessor in 2017. While campaigning, he walked a line between standing up for the moderate stances he had in the Legislature — like supporting Roe v. Wade — and appealing to Republicanswho embraced Trump, particularly on cultural issues that have captured attention across the country.

 

Ciattarelli, who stepped down as state Assembly member in 2018 to run for governor, founded a medical publishing company called Galen Publishing, and held local and county positions in Somerset.

 

Murphy’s win also ends the more than three-decade-old trend of the party opposite the president’s winning in New Jersey’s off-year governor’s race.

 

The 64-year-old governor said he was acutely aware of the political trends, calling them an “animating” force for his reelection effort that spurred him to run as if he were 10 points behind.

 

Murphy built his campaign around the progressive accomplishments he signed into law — like a phased-in $15 an hour minimum wage and paid sick leave along with taxes on the wealthy — and brought on Democratic allies, like progressive U.S. Sen. Bernie Sanders, to campaign for him.

 

With a Democrat-led Legislature, Murphy achieved most of the promises he made in his first run four years ago when he vied to succeed Republican Chris Christie. Taxpayer-financed community college and some pre-K, tighter gun laws, expanded voting access, recreational marijuana, more state aid for schools and a fully funded public pension — all promised and all delivered during the first term. A proposal for a public bank to finance projects went unfulfilled.

 

Murphy is a former Goldman Sachs executive and served as ambassador to Germany under former President Barack Obama, who campaigned for Murphy in the weeks before Election Day.

 

He has said his next term will be about enacting a Reproductive Freedom Act aimed at codifying Roe v. Wade in the state as well as additional gun control laws and the expansion of taxpayer-financed pre-K for 3-year-olds.

 

Headwinds facing Democrats, like President Joe Biden’s falling approval ratings and congressional Democrats’ struggles to enact their agenda, didn’t factor heavily enough into some experts’ preelection analysis, said Ben Dworkin, the director of Rowan University’s Institute for Public Policy & Citizenship. He counted himself among them.

 

A spokesperson for Ciattarelli said Wednesday that the campaign was focused on the vote count and said a possible legal pursuit of a recount was on the table. Murphy also called Wednesday morning for every vote to be counted.

 

New Jersey does not have an automatic recount law, but the candidates are permitted to request one. The party that wants a recount must file a suit in State Superior Court in the counties where they want to contest tallies. That has to be done within 17 days of Election Day.

 

Associated Press Writer Mike Catalini reports

Associated Press Writer Christina Paciolla contributed to this report.

Categories
Local News Politics

Polls still open until after dark for N.J. Decides 2021

Tuesday is the final day for voters to cast a ballot in the New Jersey race for governor. Voters can postmark their mail-in ballots today, or vote at the polls.

 

There are at least five names to choose from, but the two main party candidates are sure to be the top vote-getters. Polls have shown for months that Gov. Phil Murphy, a 64-year-old Democrat, has a comfortable lead — as much as 11 points according to a Monmouth University poll released last week.

 

But there is one major factor working against the governor. If Murphy is Tuesday’s victor, he’ll be the first Democratic governor to be reelected in New Jersey since Brenden Byrne in 1977. That’s even though the state has about a million more registered Democrats than Republicans.

 

The ongoing issue for Democrats in statewide elections is that New Jersey homeowners pay the highest property taxes in the county and Murphy’s challenger, Republican Jack Ciattarelli, reminds voters of that every chance he gets.

 

Ciattarelli, 59, is a business owner and former member of the New Jersey legislature. He calls Murphy a “tax and spend liberal.” If elected, he says he’ll cut the taxes, but what is unusual this time around is that Murphy makes no bones about New Jersey being a high tax state. Instead of promising to cut them, Murphy told member station WNYC that residents get good value for their high taxes: “That means the best public schools in America. It means among the best health care systems in America. It means a location second to none that we need to invest aggressively in.”

 

Murphy’s honesty about taxes has picked up support from some unlikely quarters. “He’s honest about what he believes,” says Harry Hurley, the host of a conservative talk radio show for WPGG, which broadcasts in the Republican-leaning southern part of the state.

 

“I will tell you that I had great respect for him. He campaigned saying he was going to raise certain taxes, and nobody does that. They lie. They lie to get elected and then they raise the taxes.”

 

Murphy is a former investment banker with Goldman Sachs who spent his own money to run for governor in 2017. He accomplished nearly everything he campaigned on four years ago. He raised taxes on millionaires, made community college free for those who can’t afford it, raised the minimum wage and kick-started a wind energy sector that now leads the region. But polls show the reason he’s leading the race is due to something he didn’t plan on.

 

“At the end of the day, Murphy’s handling of COVID is really going to be the determination for most people,” says Matt Hale, a professor of political science at Seton Hall University in South Orange, N.J.

 

“He’s done a very workmanlike, very professional and very quiet job, but I think that’s exactly what people want.”

 

New Jersey was one of the first states to be hit by the public health crisis, and it came at a particularly bad time for the governor. In early March, Murphy underwent surgery for a cancerous tumor on his kidney, just as the spread of COVID in New York and New Jersey was becoming apparent. He kept up on developments from his hospital bed and quickly moved to shut down the state.

 

He soon was holding daily briefings that would draw thousands of viewers online. Despite the high marks for his leadership during the pandemic, possibly the biggest blemish on his first term will be the almost 8,000 deaths at nursing homes in a little more than a year, including two facilities for veterans.

 

Murphy defends his record, saying the state was hurt by being among the first to face the pandemic, without adequate supplies of protective equipment or anyplace to send residents when they were ready to return home from the hospital.

 

Ciattarelli does not support mask mandates for school kids or vaccine mandates, both of which poll strongly in New Jersey, especially among parents like Monica Schaefer, who is in her 50s and has kids in the schools in Chatham, a suburb that’s evenly split between Democrats and Republicans.

 

She says she thinks the mandates in school are really important because they help everyone, not just students. “I’m a true believer in unions and for our teachers, and it protects our teachers, and I think it’s important to keep them on staff, and it’s important that they’re protected.”

 

If elected, Ciattarell has promised to lower property taxes, redistribute the extra funding that poor school districts are given to suburban communities. He was known as a moderate during his time in Trenton as a member of the state legislature, but ran to the right during his primary, attending a “Stop the Steal” rally on January 6, the day of the Capitol riot.

 

He has also promised to roll back police reforms, prohibit abortions after 20 weeks and slow the climate change actions taken by Murphy.

 

The other odd-year gubernatorial election happening this year is in Virginia, where Democrat Terry McAuliffe is locked in a dead heat with Republican Glenn Youngkin.

 

— NPR

Categories
Lifestyle Local News Politics

Senator cites discrimination against some dog breeds in N.J. homeowners insurance

Sen. Lesniak recently calls on the State Legislature to ban the discrimination in homeowners insurance against certain breeds of dogs.

 

Specifically, he cited Travelers and GEICO Insurance Companies for their discrimination against a long list of breeds of dogs in their homeowners insurance applications.

 

“Here’s what Travelers asks,” said Lesniak, “Do you or any household member own one or more of the following breeds or a mix of one of these breeds of dogs: Akita, Alaskan Malamute, American Bull Terrier, American Staffordshire Terrier, Mastiffs, Chow Chow, Doberman Pinscher, Pit Bull, Presa Canario, Rottweiler, Staffordshire Bull Terrier, Wolf Hybrid.”

 

“What, no poodles?” Lesniak questioned. “GEICO has a similar list, though not as extensive,” Lesniak added.

 

“I have two mixed breed rescue dogs: pit bull, doberman pinscher and rottweiler. The only danger they present is that they could love you to death,” Lesniak explained, “Additionally, the insurance companies’ practice discourages adoption of rescue dogs, many of which have unknown breeding or fall into the laundry list of prohibited breeds.”

 

Lesniak praised insurance companies which do not discriminate against certain dog breeds and added, “this inhumane insurance company practice must be stopped.”

 

About The Lesniak Institute for American Leadership 

 The Lesniak Institute is developing the next generation of American leaders by teaching the principles of effective advocacy, offering first-hand experience through its causes, and partnering with grassroots organizations. The Institute is named for Senator Raymond J. Lesniak who authored and sponsored hundreds of laws during his 40 years in the New Jersey Legislature to advance human rights and the quality of life for millions. LesniakInstitute.org

Categories
Business Local News

OpenLegacy names hyper-growth marketer Asif Muhammad as chief marketing officer

  • Asif is expanding OpenLegacy’s global market presence and its banking/insurance sector customer base
  • Will drive innovation by building partner ecosystems, growth teams, brand personality, and experience consistency
  • Will align products with customer feedback and needs to ensure best-in-breed solutions

 

PRINCETON, N.J. — (BUSINESS WIRE) — #fintech—OpenLegacy, which transforms monolithic mainframe systems into cloud-native building blocks of innovation, today announced hyper-growth marketer Asif Muhammad as their new Chief Marketing Officer.


Asif brings with him two decades of technology marketing experience. This includes marketing leadership roles with the world-class brands Microsoft, IBM, and NetApp, as well as with hyper-growth startups, most recently UiPath. He boasts a number of graduate and postgraduate degrees in marketing and business administration.

 

Asif’s proven track record of success will help OpenLegacy build brand recognition, continue its exponential growth in customer adoption, and attract top talent to further advance its customer benefits. OpenLegacy partners also stand to benefit from Asif’s strong network of colleagues and like-minded professionals who will help forge new connections and strengthen existing ones to support a growing marketplace of global customers. A burgeoning movement of executives leaving traditional global companies for the more disruptive, innovation-driven tech space points to a newfound awareness of the steps large companies must take to stay competitive in today’s fintech/insurtech market.

 

“Modern marketing is about elevating the business and connecting with customers by delivering a distinct, valued, and consistent experience,” explains Asif. “This requires a business mindset and broad commercial experience that fuses together essential elements, brings ideas to life, and delivers impact. OpenLegacy shares my business mindset and is poised for exponential growth at the leading edge of digital transformation. In joining this growing team providing dynamic solutions like OL Hub, I help support the company’s continued growth in global markets,” Asif states.

 

OpenLegacy’s data-driven OpenLegacy (OL) Hub modernization platform empowers businesses to efficiently build new digital services reusing monolithic core legacy assets. Enterprises ranging from banks to insurance providers quickly generate business-level APIs with the ease of a cloud-native app for deployment across any digital platform.

 

“Asif has a successful track record of building, launching, and scaling multimillion-dollar products and solutions on a global scale,” enthuses OpenLegacy CEO Romi Stein. “We will leverage his strengths growing market positions in hyper-competitive markets to help elevate OpenLegacy’s standing in the global banking and insurance industries.” Stein concludes, “Asif’s deep experience creating best-in-class teams and helping them embrace and thrive with change will be instrumental in taking us to the next level on the world stage.”

 

OL Hub supports the automation of the entire integration process to help companies achieve their digital journey at speed. Learn more here.

 

OL Hub is now available for cloud-based free trials or you can schedule a remote-based product demo here.

 

About OpenLegacy

OpenLegacy’s Digital-Driven Integration enables organizations with legacy systems to release new digital services faster and more efficiently than ever before. It connects directly to even the most complex legacy systems, bypassing the need for extra layers of technology. It then automatically generates APIs in minutes, rapidly integrating those assets into new and exciting innovations. Finally, it deploys them as standard microservices or serverless functions, giving organizations speed and flexibility while drastically cutting costs and resources. With OpenLegacy, industry leading companies release new apps, features, and updates in days instead of months, enabling them to truly become digital to the core. Learn why leading companies choose OpenLegacy at openlegacy.com, and follow us on Twitter or LinkedIn.

 

About Asif Muhammad

As the Chief Marketing Officer, Asif leads all aspects of global marketing, including product, brand building, growth, partnership and sales enablement. Asif brings with him 20 years of technology marketing experience at hyper-growth tech companies. Prior to joining OpenLegacy, he held marketing leadership roles at Microsoft, IBM, NetApp, and most recently at UiPath, which went public in April 2021. At UiPath, Asif built the Field & Partner Alliances function from scratch, scaling it globally.

 

Asif holds a BA in Economics, MBA from Preston University, MA in Marketing Management from Birmingham City University, and PgdCIM, FCIM, MCIM and Chartered Marketer status from the University of West London.

Contacts

Media Contact
Treble
Katie LeChase

openlegacy@treblepr.com

Categories
Culture Local News

Hang out with birds, bats, and bugs for the Masquerade Parade by D&R Greenway Land Trust on Halloween Day

PRINCETON, N.J. – Expecting carloads of parade-goers, D&R Greenway Land Trust is planning their annual Halloween Day Masquerade Parade for Sunday at historic St. Michael’s Farm Preserve in Hopewell.

 

Mutts comic artist Patric McDonnell with Masquerade Parade art
— Courtesy photo

Presenting birds, bats, and bugs…Oh my! D&R Greenway’s Masquerade Parade will take place from noon to 5 p.m. Oct. 31. To pre-register your carload of parade-goers, visit www.drgreenway.org, or come straight to the Hopewell Elementary School parking lot and register during the event. The donation is $25 per carload. Ticket purchases and Sponsorships support the land trust’s mission of preserving land and inspiring a conservation ethic now and forever.

 

A dozen colorful and unusual ‘floats’ decorated to the event theme, “Birds, Bats and Bugs”, will be positioned along the St. Michaels Farm Preserve roadway. Celebrate Halloween while enjoying the beautiful fall backdrop of St. Michaels Farm Preserve.

 

Participating ‘floats’ include FUTURO Program at Latin American Legal Defense of Education Fund (LALDEF); Hopewell Township Police Department; Bahai’is of Central New Jersey; Rutgers Master Gardeners of Mercer; Bordentown Historical Society; InnerSpace Taijiquan; Washington Crossing Audubon Society; SPLASH Steamboat Floating Classroom/D&R Greenway Land Trust’s Kayak Program; D&R Greenway Land Trust and The Chubby’s Project.

 

Sunday’s Parade offers a safe way to Trick or Treat as guests will remain in their cars, which they are encouraged to have decorated in line with the theme. Passengers are also encouraged to create lively signs identifying their favorite bird, bat, or bug along with a fun fact about their favorite creature.

Each carload will be given a nature-themed goody bag of surprises, including a newly published children’s book. Vehicles will “line up” in the Hopewell Elementary School parking lot and migrate to St. Michaels Farm Preserve at the Princeton Avenue entrance closest to town (Hopewell).

 

Every parade has live music: Ours will feature and our very own musician, Bill Flemer and Friends on D&R Greenway’s float. See best-selling cartoonist Patrick McDonnell’s specially themed Halloween painting and renowned artist James Fiorentino’s Little Brown Bat on display!

 

This drive-through, reverse parade will be held light rain or shine. If severe weather cancels our Parade, we will host a Zoom party on Friday evening, November 5th, where each group will present their creations and the audience will vote for best “float!”

 

BACKGROUND:

 

D&R Greenway Land Trust, an accredited nonprofit, has reached a new milestone of over 21,000 acres of land preserved since 1989. By preserving land for life and creating public trails, it gives everyone the opportunity to enjoy the great outdoors. The land trust’s preserved farms and community gardens provide local organic food for our neighbors—including those most in need. Through strategic land conservation and stewardship, D&R Greenway combats climate change, protects birds and wildlife, and ensures clean drinking water for future generations. D&R Greenway’s mission is centered in connecting land with people from all walks of life.

 

Visit our Facebook and Instagram pages and www.drgreenway.org to learn more.

Categories
Local News Science

Bristol Myers Squibb receives European Commission approval for Opdivo (nivolumab) + chemotherapy for patients with HER2 negative, advanced or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma …

Approval is based on positive results from the Phase 3 CheckMate -649 trial

Opdivo plus chemotherapy is the first treatment regimen to demonstrate superior overall survival and progression-free survival compared to chemotherapy alone in this patient population

 

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) + Chemotherapy for Patients with HER2 Negative, Advanced or Metastatic Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma whose Tumors Express PD-L1 with CPS ≥ 5

 

PRINCETON, N.J. — (BUSINESS WIRE) — $BMY #CheckMate —  Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo (nivolumab) in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma (EAC) whose tumors express PD-L1 with a combined positive score (CPS) ≥ 5.

The EC’s decision is based on results from the Phase 3 CheckMate -649 trial, in which first-line treatment with Opdivo plus leucovorin, 5-fluorouracil and oxaliplatin (FOLFOX) or capecitabine and oxaliplatin (CapeOX) was compared with chemotherapy alone. Results from the trial showed a statistically significant and clinically meaningful improvement in overall survival (OS) and progression-free survival (PFS) in patients with unresectable advanced or metastatic gastric cancer (GC), GEJ cancer (GEJC) or EAC whose tumors express PD-L1 with a CPS ≥ 5 (the primary endpoints of the study). The statistically significant OS benefit shown with Opdivo plus chemotherapy was also observed in PD-L1 positive patients with CPS ≥ 1 and in the all-randomized population. The safety profile observed for Opdivo plus chemotherapy in the CheckMate -649 trial was consistent with the known safety profiles of the individual treatments.

 

“This approval marks a great achievement for many patients with gastric, gastroesophageal junction and esophageal adenocarcinomas, who now have a new treatment option that has demonstrated superior overall survival compared to the long-standing standard of care,” said Ian M. Waxman, M.D., development lead, gastrointestinal cancers, Bristol Myers Squibb. “With limited advances for HER2-negative gastric cancers made in the past ten years, we are especially pleased to move the field forward and introduce this Opdivo-based combination for patients in the European Union.”

 

The EC approval allows for the use of Opdivo in combination with fluoropyrimidine and platinum-based combination chemotherapy for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric cancer, gastroesophageal junction (GEJ), or esophageal adenocarcinoma (EAC), whose tumors express PD-L1 with a combined positive score (CPS) ≥ 5 in the 27 member states of the European Union, as well as Iceland, Liechtenstein, and Norway.

 

CheckMate -649 Efficacy and Safety Results in Patients with PD-L1 CPS ≥ 5

Results from CheckMate -649 include:

  • OS (minimum follow‑up of 19.4 months): Median OS was 14.4 months in patients receiving Opdivo plus chemotherapy (95% Confidence Interval [CI]: 13.1 to 16.3) compared to 11.1 months (95% CI: 10.0 to 12.1) in patients receiving chemotherapy alone (Hazard Ratio [HR] 0.69; 95% CI: 0.60 to 0.81).
  • PFS (minimum follow‑up of 19.4 months): Median PFS was 8.31 months in patients receiving Opdivo plus chemotherapy (95% CI: 7.03 to 9.26) vs. 6.05 months (95% CI: 5.55 to 6.90) in patients receiving chemotherapy alone (HR = 0.68; 95% CI: 0.59 to 0.79).
  • Safety: The most frequent adverse reactions were peripheral neuropathy (53%), nausea (48%), fatigue (44%), diarrhea (39%), vomiting (31%), decreased appetite (29%), abdominal pain (27%), constipation (25%), musculoskeletal pain (20%), pyrexia (19%), rash (18%), stomatitis (17%), palmar-plantar erythrodysaesthesia syndrome (13%), cough (13%), oedema (including peripheral oedema) (12%), headache (11%), and upper respiratory tract infection (10%).

 

About CheckMate -649

CheckMate -649 is a Phase 3 randomized, multi-center, open-label study evaluating Opdivo plus chemotherapy or the Opdivo plus Yervoy combination compared to chemotherapy alone in patients with previously untreated, non-HER2-positive, advanced or metastatic gastric cancer, gastroesophageal junction cancer or esophageal adenocarcinoma. Patients in the Opdivo plus chemotherapy arm received Opdivo 360 mg plus capecitabine and oxaliplatin (CapeOX) every three weeks or Opdivo 240 mg plus 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX) every two weeks. Patients in the Opdivo plus Yervoy arm received Opdivo 1 mg/kg plus Yervoy 3 mg/kg every three weeks for four cycles followed by Opdivo 240 mg every two weeks. Patients in the chemotherapy arm received FOLFOX or CapeOX every two or three weeks, respectively. All patients continued treatment for two years or until disease progression, unacceptable toxicity or withdrawal of consent. The primary endpoints of the trial are overall survival (OS) in PD-L1 positive patients with a combined positive score (CPS) ≥ 5 treated with Opdivo plus chemotherapy and PFS, as assessed by Blinded Independent Central Review (BICR), in CPS ≥ 5 patients treated with Opdivo plus chemotherapy compared to chemotherapy alone. Secondary endpoints include OS in CPS ≥ 1 and all randomized patients treated with Opdivo plus chemotherapy as well as OS and time to symptom deterioration (TTSD) in patients treated with Opdivo plus Yervoy compared to chemotherapy alone.

 

About Gastric Cancer

Gastric cancer, also known as stomach cancer, is the fifth most common cancer and the fourth leading cause of cancer death worldwide, with over 1,000,000 new cases and approximately 770,000 deaths in 2020. There are several cancers that can be classified as gastric cancer, including certain types of cancers that form in the gastroesophageal junction, the area of the digestive tract where the esophagus and stomach connect. While GEJ cancer has a lower prevalence than distal gastric cancer, it continues to rise.

 

About Esophageal Cancer

Esophageal cancer is the seventh most common cancer and the sixth leading cause of death from cancer worldwide, with approximately 600,000 new cases and over 540,000 deaths in 2020. The two most common types of esophageal cancer are squamous cell carcinoma and adenocarcinoma, which account for approximately 85% and 15% of all esophageal cancers, respectively, though esophageal tumor histology can vary by region with the highest rate of esophageal adenocarcinoma occurring in North America (65%) and Europe (~40%).

 

Bristol Myers Squibb: Creating a Better Future for People with Cancer

Bristol Myers Squibb is inspired by a single vision — transforming people’s lives through science. The goal of the company’s cancer research is to deliver medicines that offer each patient a better, healthier life and to make cure a possibility. Building on a legacy across a broad range of cancers that have changed survival expectations for many, Bristol Myers Squibb researchers are exploring new frontiers in personalized medicine, and through innovative digital platforms, are turning data into insights that sharpen their focus. Deep scientific expertise, cutting-edge capabilities and discovery platforms enable the company to look at cancer from every angle. Cancer can have a relentless grasp on many parts of a patient’s life, and Bristol Myers Squibb is committed to taking actions to address all aspects of care, from diagnosis to survivorship. Because as a leader in cancer care, Bristol Myers Squibb is working to empower all people with cancer to have a better future.

 

About Opdivo

Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.

 

Opdivo’s leading global development program is based on Bristol Myers Squibb’s scientific expertise in the field of Immuno-Oncology and includes a broad range of clinical trials across all phases, including Phase 3, in a variety of tumor types. To date, the Opdivo clinical development program has treated more than 35,000 patients. The Opdivo trials have contributed to gaining a deeper understanding of the potential role of biomarkers in patient care, particularly regarding how patients may benefit from Opdivo across the continuum of PD-L1 expression.

 

In July 2014, Opdivo was the first PD-1 immune checkpoint inhibitor to receive regulatory approval anywhere in the world. Opdivo is currently approved in more than 65 countries, including the United States, the European Union, Japan and China. In October 2015, the Company’s Opdivo and Yervoy combination regimen was the first Immuno-Oncology combination to receive regulatory approval for the treatment of metastatic melanoma and is currently approved in more than 50 countries, including the United States and the European Union.

 

About Yervoy

Yervoy is a recombinant, human monoclonal antibody that binds to the cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4). CTLA-4 is a negative regulator of T-cell activity. Yervoy binds to CTLA-4 and blocks the interaction of CTLA-4 with its ligands, CD80/CD86. Blockade of CTLA-4 has been shown to augment T-cell activation and proliferation, including the activation and proliferation of tumor infiltrating T-effector cells. Inhibition of CTLA-4 signaling can also reduce T-regulatory cell function, which may contribute to a general increase in T-cell responsiveness, including the anti-tumor immune response. On March 25, 2011, the U.S. Food and Drug Administration (FDA) approved Yervoy 3 mg/kg monotherapy for patients with unresectable or metastatic melanoma. Yervoy is approved for unresectable or metastatic melanoma in more than 50 countries. There is a broad, ongoing development program in place for Yervoy spanning multiple tumor types.

 

INDICATIONS

OPDIVO® (nivolumab), as a single agent, is indicated for the treatment of patients with unresectable or metastatic melanoma.

OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab), is indicated for the treatment of patients with unresectable or metastatic melanoma.

 

OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab), is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.

 

OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab) and 2 cycles of platinum-doublet chemotherapy, is indicated for the first-line treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.

 

OPDIVO® (nivolumab) is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO.

 

OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab), is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma (MPM).

 

OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab), is indicated for the first-line treatment of patients with intermediate or poor risk advanced renal cell carcinoma (RCC).

 

OPDIVO® (nivolumab), in combination with cabozantinib, is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC).

 

OPDIVO® (nivolumab) is indicated for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.

 

OPDIVO® (nivolumab) is indicated for the treatment of adult patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin or after 3 or more lines of systemic therapy that includes autologous HSCT. This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

 

OPDIVO® (nivolumab) is indicated for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after platinum-based therapy.

 

OPDIVO® (nivolumab) is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

 

OPDIVO® (nivolumab), as a single agent, is indicated for the adjuvant treatment of patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC.

 

OPDIVO® (nivolumab), as a single agent, is indicated for the treatment of adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

 

OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab), is indicated for the treatment of adults and pediatric patients 12 years and older with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

 

OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab), is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

 

OPDIVO® (nivolumab) is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection.

 

OPDIVO® (nivolumab) is indicated for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.

 

OPDIVO® (nivolumab) is indicated for the adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy (CRT).

 

OPDIVO® (nivolumab), in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma.

 

IMPORTANT SAFETY INFORMATION

Severe and Fatal Immune-Mediated Adverse Reactions

Immune-mediated adverse reactions listed herein may not include all possible severe and fatal immune-mediated adverse reactions.

 

Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue. While immune-mediated adverse reactions usually manifest during treatment, they can also occur after discontinuation of OPDIVO or YERVOY. Early identification and management are essential to ensure safe use of OPDIVO and YERVOY. Monitor for signs and symptoms that may be clinical manifestations of underlying immune-mediated adverse reactions. Evaluate clinical chemistries including liver enzymes, creatinine, adrenocorticotropic hormone (ACTH) level, and thyroid function at baseline and periodically during treatment with OPDIVO and before each dose of YERVOY. In cases of suspected immune-mediated adverse reactions, initiate appropriate workup to exclude alternative etiologies, including infection. Institute medical management promptly, including specialty consultation as appropriate.

 

Withhold or permanently discontinue OPDIVO and YERVOY depending on severity (please see section 2 Dosage and Administration in the accompanying Full Prescribing Information). In general, if OPDIVO or YERVOY interruption or discontinuation is required, administer systemic corticosteroid therapy (1 to 2 mg/kg/day prednisone or equivalent) until improvement to Grade 1 or less. Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month. Consider administration of other systemic immunosuppressants in patients whose immune-mediated adverse reactions are not controlled with corticosteroid therapy. Toxicity management guidelines for adverse reactions that do not necessarily require systemic steroids (e.g., endocrinopathies and dermatologic reactions) are discussed below.

 

Immune-Mediated Pneumonitis

OPDIVO and YERVOY can cause immune-mediated pneumonitis. The incidence of pneumonitis is higher in patients who have received prior thoracic radiation. In patients receiving OPDIVO monotherapy, immune-mediated pneumonitis occurred in 3.1% (61/1994) of patients, including Grade 4 (<0.1%), Grade 3 (0.9%), and Grade 2 (2.1%). In patients receiving OPDIVO 1 mg/kg with YERVOY 3 mg/kg every 3 weeks, immune-mediated pneumonitis occurred in 7% (31/456) of patients, including Grade 4 (0.2%), Grade 3 (2.0%), and Grade 2 (4.4%). In patients receiving OPDIVO 3 mg/kg with YERVOY 1 mg/kg every 3 weeks, immune-mediated pneumonitis occurred in 3.9% (26/666) of patients, including Grade 3 (1.4%) and Grade 2 (2.6%). In NSCLC patients receiving OPDIVO 3 mg/kg every 2 weeks with YERVOY 1 mg/kg every 6 weeks, immune-mediated pneumonitis occurred in 9% (50/576) of patients, including Grade 4 (0.5%), Grade 3 (3.5%), and Grade 2 (4.0%). Four patients (0.7%) died due to pneumonitis.

 

In Checkmate 205 and 039, pneumonitis, including interstitial lung disease, occurred in 6.0% (16/266) of patients receiving OPDIVO. Immune-mediated pneumonitis occurred in 4.9% (13/266) of patients receiving OPDIVO, including Grade 3 (n=1) and Grade 2 (n=12).

 

Immune-Mediated Colitis

 

OPDIVO and YERVOY can cause immune-mediated colitis, which may be fatal. A common symptom included in the definition of colitis was diarrhea. Cytomegalovirus (CMV) infection/reactivation has been reported in patients with corticosteroid-refractory immune-mediated colitis. In cases of corticosteroid-refractory colitis, consider repeating infectious workup to exclude alternative etiologies. In patients receiving OPDIVO monotherapy, immune-mediated colitis occurred in 2.9% (58/1994) of patients, including Grade 3 (1.7%) and Grade 2 (1%). In patients receiving OPDIVO 1 mg/kg with YERVOY 3 mg/kg every 3 weeks, immune-mediated colitis occurred in 25% (115/456) of patients, including Grade 4 (0.4%), Grade 3 (14%) and Grade 2 (8%). In patients receiving OPDIVO 3 mg/kg with YERVOY 1 mg/kg every 3 weeks, immune-mediated colitis occurred in 9% (60/666) of patients, including Grade 3 (4.4%) and Grade 2 (3.7%).

 

Immune-Mediated Hepatitis and Hepatotoxicity

 

OPDIVO and YERVOY can cause immune-mediated hepatitis. In patients receiving OPDIVO monotherapy, immune-mediated hepatitis occurred in 1.8% (35/1994) of patients, including Grade 4 (0.2%), Grade 3 (1.3%), and Grade 2 (0.4%). In patients receiving OPDIVO 1 mg/ kg with YERVOY 3 mg/kg every 3 weeks, immune-mediated hepatitis occurred in 15% (70/456) of patients, including Grade 4 (2.4%), Grade 3 (11%), and Grade 2 (1.8%). In patients receiving OPDIVO 3 mg/kg with YERVOY 1 mg/kg every 3 weeks, immune-mediated hepatitis occurred in 7% (48/666) of patients, including Grade 4 (1.2%), Grade 3 (4.9%), and Grade 2 (0.4%).

 

OPDIVO in combination with cabozantinib can cause hepatic toxicity with higher frequencies of Grade 3 and 4 ALT and AST elevations compared to OPDIVO alone. Consider more frequent monitoring of liver enzymes as compared to when the drugs are administered as single agents. In patients receiving OPDIVO and cabozantinib, Grades 3 and 4 increased ALT or AST were seen in 11% of patients.

 

Immune-Mediated Endocrinopathies

OPDIVO and YERVOY can cause primary or secondary adrenal insufficiency, immune-mediated hypophysitis, immune-mediated thyroid disorders, and Type 1 diabetes mellitus, which can present with diabetic ketoacidosis. Withhold OPDIVO and YERVOY depending on severity (please see section 2 Dosage and Administration in the accompanying Full Prescribing Information). For Grade 2 or higher adrenal insufficiency, initiate symptomatic treatment, including hormone replacement as clinically indicated. Hypophysitis can present with acute symptoms associated with mass effect such as headache, photophobia, or visual field defects. Hypophysitis can cause hypopituitarism; initiate hormone replacement as clinically indicated. Thyroiditis can present with or without endocrinopathy. Hypothyroidism can follow hyperthyroidism; initiate hormone replacement or medical management as clinically indicated. Monitor patients for hyperglycemia or other signs and symptoms of diabetes; initiate treatment with insulin as clinically indicated.

 

In patients receiving OPDIVO monotherapy, adrenal insufficiency occurred in 1% (20/1994), including Grade 3 (0.4%) and Grade 2 (0.6%). In patients receiving OPDIVO 1 mg/kg with YERVOY 3 mg/kg every 3 weeks, adrenal insufficiency occurred in 8% (35/456), including Grade 4 (0.2%), Grade 3 (2.4%), and Grade 2 (4.2%). In patients receiving OPDIVO 3 mg/kg with YERVOY 1 mg/kg every 3 weeks, adrenal insufficiency occurred in 7% (48/666) of patients, including Grade 4 (0.3%), Grade 3 (2.5%), and Grade 2 (4.1%). In patients receiving OPDIVO and cabozantinib, adrenal insufficiency occurred in 4.7% (15/320) of patients, including Grade 3 (2.2%) and Grade 2 (1.9%).

 

In patients receiving OPDIVO monotherapy, hypophysitis occurred in 0.6% (12/1994) of patients, including Grade 3 (0.2%) and Grade 2 (0.3%). In patients receiving OPDIVO 1 mg/kg with YERVOY 3 mg/kg every 3 weeks, hypophysitis occurred in 9% (42/456), including Grade 3 (2.4%) and Grade 2 (6%). In patients receiving OPDIVO 3 mg/kg with YERVOY 1 mg/kg every 3 weeks, hypophysitis occurred in 4.4% (29/666) of patients, including Grade 4 (0.3%), Grade 3 (2.4%), and Grade 2 (0.9%).

In patients receiving OPDIVO monotherapy, thyroiditis occurred in 0.6% (12/1994) of patients, including Grade 2 (0.2%). In patients receiving OPDIVO 3 mg/kg with YERVOY 1 mg/kg every 3 weeks, thyroiditis occurred in 2.

Contacts

Bristol Myers Squibb

Media Inquiries:
Media@BMS.com

Investors:
Tim Power

609-252-7509

timothy.power@bms.com

Nina Goworek

908-673-9711

nina.goworek@bms.com

Read full story here

Categories
Business Local News

BIM accelerates digital transformation in the global AEC industry

New study from Dodge Data & Analytics and Autodesk suggests that BIM is the cornerstone of the shift to digital in the AEC industry.

HAMILTON, N.J. — (BUSINESS WIRE)–Architecture, engineering and construction (AEC) is increasingly becoming a data-driven industry, and a new study by Dodge Data & Analytics, conducted in partnership with Autodesk, demonstrates that building information modeling (BIM) is at the heart of that initiative. The findings are featured in the Accelerating Digital Transformation Through BIM SmartMarket Report, which provides a thorough overview of how architects, engineers and contractors are deploying BIM, and how they leverage the data from models and processes to improve decision-making and effectively power integrated digital workflows among project team members.

One of the most important findings of the study is the correlation between the depth of engagement with data-driven BIM processes, the intensity of BIM use (the share of projects on which BIM is used), and the degree to which the benefits of using BIM are experienced.

 

  • For architects and engineers, critical benefits—including business benefits like improved client satisfaction and design quality, risk reduction through increased stakeholder buy-in and reduced errors and rework, and additional meaningful sustainability and operational efficiency benefits—are experienced at a much higher level by those who are highly engaged with BIM.
  • Contractors with a deeper engagement with BIM also experience crucial benefits to a higher degree, including business benefits like improved win rates and increased percentage of successful projects, quality benefits like a reduced number of constructability issues onsite and reduced defects at handover, and many cost control, schedule and safety benefits, compared with those who are less engaged.

 

”The findings of this report are consistent with what we hear directly from our customers: the greater the embrace of BIM, the greater returns they see,” said Amy Bunszel, executive vice president, AEC Design Solutions, Autodesk. “BIM is the foundation of the digital transformation of the industry, from design through operations, and as owners begin to look ahead to a digital twin future, all stakeholders should begin their digital journey now.”

 

The report also suggests that BIM is a critical factor in a company’s larger process of digital transformation. The design and construction industries are continuing to explore the use of data and digital tools to improve the outcomes of projects. The study suggests that BIM is a critical part of the digital transformation journey, with nearly half (47%) of high intensity BIM users approaching or near to achieving the goal of digital transformation, compared with just 26% of BIM users generally.

 

The study also offers insight into where the industry currently stands by providing a benchmark for the use of various digital technologies and approaches in five categories: design intelligence tools, innovative construction methods, jobsite technology, smart building technology and data-sharing technology.

 

  • Among those, the top technologies in use currently among BIM users are cloud computing (42%), model-based simulation (33%), virtual/augmented/mixed reality (28%), 3D printing (25%) and reality capture (25%).
  • Technologies most strongly poised for growth, with a relatively high percentage who expect to adopt them in the next two to three years, include generative/outcome-based design (20%), 3D printing (19%), model-driven prefabrication (18%), model-driven simulation (18%), robotics/automated equipment (18%), reality capture (17%) and AI/machine learning (17%).

 

“This study demonstrates that the data revolution is already underway in design and construction,” says Steve Jones, Senior Director, Industry Insights at Dodge Data & Analytics. “As the industry adopts tools like generative design, machine learning, reality capture and automated vehicles, we can expect to see better performing buildings, more profitable projects, increases in safety and improved efficiency onsite.”

 

The full report includes more detailed data on critical aspects of BIM deployment, like use of the cloud and a common data environment for digital workflows, the means to maximize the return on investment experienced from BIM and team engagement with the use of BIM. In addition, it also features case studies and thought leader perspectives on the future of BIM. The full report is available for free download at www.construction.com.

 

About Dodge Data & Analytics: Dodge Data & Analytics is North America’s leading provider of commercial construction project data, market forecasting, and analytics services and workflow integration solutions for the construction industry. Building product manufacturers, architects, engineers, contractors, and service providers leverage Dodge to identify and pursue unseen growth opportunities that help them grow their business. On a local, regional or national level, Dodge empowers its customers to better understand their markets, uncover key relationships, seize growth opportunities, and pursue specific sales opportunities with success. The company’s construction project information is the most comprehensive and verified in the industry.

 

As of April 15th, Dodge Data & Analytics and The Blue Book — the largest, most active network in the U.S. commercial construction industry — combined their businesses in a merger. The Blue Book Network delivers three unparalleled databases of companies, projects, and people. Dodge and The Blue Book offer 10+ billion data elements and 14+ million project and document searches. Together, they provide a unified approach for new business generation, business planning, research, and marketing services users can leverage to find the best partners to complete projects and to engage with customers and prospects to promote projects, products, and services. To learn more, visit: construction.com and thebluebook.com.

Contacts

Cailey Henderson

104 West Partners

dodge@104west.com

Categories
Business Local News

BTRS Holdings Inc. to hold third quarter 2021 earnings call on November 10, 2021

LAWRENCEVILLE, N.J. — (BUSINESS WIRE) — BTRS Holdings Inc. (“Billtrust” or “the Company”) (NASDAQ: BTRS), a B2B accounts receivable automation and integrated payments leader, today announced it will discuss its third quarter 2021 financial results on Wednesday, November 10, 2021 at 5:00 pm ET. Hosting the call will be Flint Lane, Founder and Chief Executive Officer, and Mark Shifke, Chief Financial Officer.

The conference call will be webcast live from the investor relations portion of the Company’s website at https://www.billtrust.com/about/investors. A replay will be available on the investor relations website following the call.

 

The conference call can also be accessed live over the phone by dialing 877-407-3982 (toll free) or 201-493-6780 (international). A replay will be available approximately one hour after the call has concluded and can be accessed by dialing 844-512-2921 (toll free) or 412-317-6671 (international); the conference ID is 13724066. The replay will be available through Wednesday November 24, 2021.

 

About BTRS Holdings

Billtrust (NASDAQ: BTRS) is a leading provider of cloud-based software and integrated payment processing solutions that simplify and automate B2B commerce. Accounts receivable is broken and relies on conventional processes that are outdated, inefficient, manual and largely paper based. Billtrust is at the forefront of the digital transformation of AR, providing mission-critical solutions that span credit decisioning and monitoring, online ordering, invoice delivery, payments and remittance capture, invoicing, cash application and collections.

 

For more information, visit Billtrust.com.

Contacts

Investor:

John T. Williams

ir@billtrust.com

Media:

Meredith Simpson

msimpson@billtrust.com

Categories
Business Local News

Mercer County successfully host latest ‘drive-thru’ job fair

TRENTON, N.J. — Mercer County recently offered job seekers an inventive way to discover employment opportunities by bypassing the customary meet and greet of traditional job fairs and, instead, having residents stay in their cars.

 

On Sept. 29, for the third time during the coronavirus pandemic, Mercer County One-Stop Career Center conducted a “Drive Thru” job fair at CURE Insurance Arena in Trenton.

 

At the fair, visitors receive packets of information from the 85-plus potential employers who participated. More than 460 vehicles — some of which had multiple occupants — attended the event and gathered information on opportunities in manufacturing, warehousing, health care, food service, retail, community agencies, customer service, government and more.

 

“Offering a drive-up fair allows us to provide a much-needed service while keeping attendees, our employees and participants as safe as we can during this pandemic,” said Mercer County Executive Brian M. Hughes.

 

“Individuals were able to obtain information without the anxiety of meeting employers if they were not ready to do so. They were also able to obtain a wide array of employment possibilities in one stop. In their own time, they have the opportunity to review in depth the job information provided to them,” Mr. Hughes added.

 

The job fair is not the last connection job seekers will have with the Mercer County One-Stop Career Center. “We know that connecting people to jobs and services often requires multiple touch points, and the job fair is just one interaction on the journey,” Mr. Hughes said.

 

All who attended received a follow-up email listing the names and websites of employer participants. The One-Stop also notifies fair-goers about other upcoming hiring events and informs them about services available to them at the One-Stop, such as job training, resume building and access to online skill-building programs.

 

”Events such as our drive-up job fair are among the many ways Mercer County has exercised creativity in how we deliver services to our residents that most need it,” Mr. Hughes said.

 

The One-Stop consistently offers multiple virtual job recruitment opportunities. For more information go to https://www.mercercounty.org/departments/one-stop-career-center/

Categories
Business Local News

Universal Display Corporation announces third quarter 2021 conference call

EWING, N.J. — (BUSINESS WIRE) — $OLED #OLED—Universal Display Corporation (Nasdaq: OLED), enabling energy-efficient displays and lighting with its UniversalPHOLED® technology and materials, today announced its results for the third quarter, ended September 30, 2021, will be released on Thursday, November 4, 2021 after market close. At that time, a copy of the financial results release will be available on the Company’s website at https://oled.com/.

In conjunction with this release, Universal Display will host a conference call on Thursday, November 4, 2021 at 5:00 p.m. Eastern Time. The live webcast of the conference call can be accessed under the events page of the Company’s Investor Relations website at ir.oled.com. Those wishing to participate in the live call should dial 1-877-524-8416 (toll-free) or 1-412-902-1028. Please dial in 5-10 minutes prior to the scheduled conference call time. An online archive of the webcast will be available within two hours of the conclusion of the call.

 

About Universal Display Corporation

Universal Display Corporation (Nasdaq: OLED) is a leader in the research, development and commercialization of organic light emitting diode (OLED) technologies and materials for use in display and solid-state lighting applications. Founded in 1994 and with subsidiaries and offices around the world, the Company currently owns, exclusively licenses or has the sole right to sublicense more than 5,000 patents issued and pending worldwide. Universal Display licenses its proprietary technologies, including its breakthrough high-efficiency UniversalPHOLED® phosphorescent OLED technology that can enable the development of energy-efficient and eco-friendly displays and solid-state lighting. The Company also develops and offers high-quality, state-of-the-art UniversalPHOLED materials that are recognized as key ingredients in the fabrication of OLEDs with peak performance. In addition, Universal Display delivers innovative and customized solutions to its clients and partners through technology transfer, collaborative technology development and on-site training. To learn more about Universal Display Corporation, please visit https://oled.com/.

 

Universal Display Corporation and the Universal Display Corporation logo are trademarks or registered trademarks of Universal Display Corporation. All other company, brand or product names may be trademarks or registered trademarks.

 

All statements in this document that are not historical, such as those relating to the Company’s technologies and potential applications of those technologies, the Company’s expected results and future declaration of dividends, as well as the growth of the OLED market and the Company’s opportunities in that market, are forward-looking financial statements within the meaning of the Private Securities Litigation Reform Act of 1995. You are cautioned not to place undue reliance on any forward-looking statements in this document, as they reflect Universal Display Corporation’s current views with respect to future events and are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated. These risks and uncertainties are discussed in greater detail in Universal Display Corporation’s periodic reports on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission, including, in particular, the section entitled “Risk Factors” in Universal Display Corporation’s Annual Report on Form 10-K for the year ended December 31, 2020. Universal Display Corporation disclaims any obligation to update any forward-looking statement contained in this document.

Follow Universal Display Corporation

Twitter
Facebook
YouTube

(OLED-C)

Contacts

Universal Display Contact:
Darice Liu

investor@oled.com
media@oled.com
+1 609-964-5123